



INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy:
EUGOGO in clinical trials
and translational research

HOTEL SPLENDID - BAVENO
LAGO MAGGIORE
APRIL 3-5, 2025



FINAL PROGRAM

INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

FINAL PROGRAM

Thursday, Apr 3rd

- | | |
|---------|--|
| 1.00 pm | Registration |
| 1.45 pm | Opening remarks: Mario Salvi, Ilaria Muller, Anja Eckstein |
| 2.00 pm | <p>Discussion of survey - suitability of EUGOGO centers for RCTs</p> <p>Chairs: <i>Anja Eckstein (Essen) & Maria Laura Tanda (Varese)</i></p> <p>Hints on the new R3 GCP focused on the role of the PI and Sponsor</p> <p><i>Francesca Degl'Innocenti (Clinical Trial Center, Milan)</i></p> <p>Self-promoted clinical trials: main topics on the design and management</p> <p><i>Giuliana Fusetti (Clinical Trial Center, Milan)</i></p> <p>Requirements for participating centers: dedicated personnel, equipment, certificates (i.e. GCP)</p> <p><i>Benedetta Montacchini (Milan)</i></p> <p>Data collection during clinical trials</p> <p><i>Beatrice Dazzi (Milan)</i></p> |
| 3.30 pm | <i>Coffee break</i> |
| 3.45 pm | <p>Reports on ongoing Clinical Trials and experience with therapeutics:</p> <p>Teprotumumab: Efficacy of teprotumumab on medical and surgical resistant DON</p> <p><i>Juliette Abeillon (Lyon)</i></p> <p>Batoclimab: Effectiveness in GO and Graves' disease</p> <p><i>Alessandro Antonelli (Pisa)</i></p> |

INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

Linsitinib: Report of preliminary results of LIDS trial

Anja Eckstein (Essen)

Veligrotug : Report of preliminary results
of THRIVE 1-2 studies

Claire Feeney (London)

Tocilizumab: Efficacy and Safety of Tocilizumab in Patients
With Active Moderate-to-Severe Corticosteroid-Resistant
TED

Tomasz Bednarczuk (Warsaw),

Milos Zarkovic (Belgrade)

The TOGO study: TCZ vs steroids

Erica Crivicich (Milan)

Satralizumab: The Satrago Study

Michele Marinò (Pisa)

Lonigutumab (Longitude 2)

TBD

Efgartigimod

Muhittin Yalcin (Ankara)

K1-70

Jane Sanders (Cardiff)

7.00 pm

Social Get together

INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

Friday, Apr 4th

- 9.00 am **Round Table:** Investigator initiated trials: how can we assess capacity of EUGOGO centers
Chair: *A.Eckstein (Essen)*
Speakers: *M. Marinò (Pisa), M. Salvi (Milan), T. Bednarczyk (Warsaw), N. Currò (Milan), S. Pitz (Frankfurt), L. Du Pasquier (Paris), J. Abeillon (Lyon)*
- 10.30 am *Coffee break*
- 10.40 am New interventional trials
C. Feeney (London) Thyroidectomy/ RAI - VL
Radiological Activity Score
- DWI MRI for GO
G. Sundar (Singapore) Imaging at diagnosis
vs. 24-36 months
and long term (5-10 yrs)
Ilaria Muller (Milano) Investigating lymphocytes resident
within target tissues to personalize
and optimize GO therapy
Michele Marinò (Pisa) The Exosome study in GO
- 12.00 pm Open questions and issues
- 1.00 pm *Lunch*
- 2.00 pm Observational / epidemiological trials
Chairs: *Cristina Burlacu (Brussels), Milos Zarkovic (Belgrade)*
Results of a French multicentric survey conducted with the
French patient organization "Vivre sans Thyroïde"
J. Abeillon (Lyon)
Survey on the Management of Mild Thyroid Eye Disease
T. Bednarczyk (Warsaw), MC Burlacu (Brussels)

INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

Ethnic variations at presentation (see PREGO) -
Comparing Caucasian & Afro-Caribbean descent and our
center with East Asian (Chinese, Japanese, Koreans),
Southeast Asian (Malays) & South Asians
(Indians, Bangladeshis, etc)

G. Sundar (Singapore)

AI algorithm for prediction and early diagnosis of GO

Mirco Armenti (Milan)

3.30 pm

Coffee break

3.45 pm

Industry-Academy EU projects (IHI 2025):
seeking industry partnership with EUGOGO centers

Marian Ludgate very brief overview of scheme

Anja Eckstein (plus EUGOGO colleagues) WP2:

Patient recruitment, sample collection, establishment of
database/registry, phone-app development etc

Monica Marazuela (plus Giulia Masetti and all participants)

WP3: Algorithm(s) to predict disease outcome/TED
phenotype based on spectrum of clinical, biochemical and
immunological analytes

Ilaria Muller (plus Steph Hannah, Gina Gortz) WP4:

Autoantibodies – TRAB titre variation within/between
patients, novel signalling cascades and antigenic targets

*Steph Hanna (plus Monica Marazuela, Ilaria Muller,
Simon Pearce)* WP5: Antigen-specific T & B cells –

their location etc

Gina Gortz (plus Essen colleagues) WP6:

In vivo model(s) - improvements to how faithfully they mimic
GD/TED, adaptation to allow effect of therapies
on reproduction

INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

Simon Pearce WP7: Clinical studies - combined therapy?

Mario Salvi (plus Monica Marazuela and EUGOGO colleagues) WP8: The orbit -imaging of TED patients, ex vivo spatial transcriptomics, in vitro OF models

Giulia Masetti WP1: Management; WP9: Consolidation & Dissemination; Future EU grant calls
Industry partners: RSR, Argenx, Merida, Acelyrin, Roche, Lundbeck, Viridian, Amgen

8.00 pm

Networking Dinner

INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy:
EUGOGO in clinical trials and translational research

Saturday, Apr 5th

- | | |
|----------|---|
| 9.00 am | EUGOGO General Assembly and budget approval
(agenda tbd) |
| 11.00 am | Organization of operational task forces and working groups |
| 11.30 am | AOB and conclusions |
-

Organizer:

Graves' Orbitopathy Center, Milan, Italy

Participants:

EUGOGO members, clinical and research collaborators, scientists

INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy:
EUGOGO in clinical trials and translational research

With unconditional contribution of



FASI s.r.l.
Via O. Tommasini 7 | 00162 Roma
Tel. 06 97605616 | Fax 06 97605650
v.toti@fasieventi.com | www.fasieventi.com

